As of 2025-05-17, the EV/EBITDA ratio of Lineage Cell Therapeutics Inc (LCTX) is -3.10. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LCTX's latest enterprise value is 60.06 mil USD. LCTX's TTM EBITDA according to its financial statements is -19.39 mil USD. Dividing these 2 quantities gives us the above LCTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-05-12 | -3.29 |
| 2025-05-09 | -2.83 |
| 2025-05-08 | -3.18 |
| 2025-05-07 | -2.87 |
| 2025-05-06 | -2.77 |
| 2025-05-05 | -3.04 |
| 2025-05-02 | -3.42 |
| 2025-05-01 | -3.58 |
| 2025-04-30 | -3.52 |
| 2025-04-29 | -3.19 |
| 2025-04-28 | -3.06 |
| 2025-04-25 | -3.42 |
| 2025-04-24 | -3.51 |
| 2025-04-23 | -3.20 |
| 2025-04-22 | -2.71 |
| 2025-04-21 | -2.36 |
| 2025-04-17 | -2.47 |
| 2025-04-16 | -2.55 |
| 2025-04-15 | -2.70 |
| 2025-04-14 | -2.88 |
| 2025-04-11 | -3.18 |
| 2025-04-10 | -2.47 |
| 2025-04-09 | -2.53 |
| 2025-04-08 | -2.19 |
| 2025-04-07 | -2.36 |
| 2025-04-04 | -2.74 |
| 2025-04-03 | -2.56 |
| 2025-04-02 | -2.79 |
| 2025-04-01 | -2.48 |
| 2025-03-31 | -2.96 |
| 2025-03-28 | -3.44 |
| 2025-03-27 | -3.49 |
| 2025-03-26 | -3.53 |
| 2025-03-25 | -3.71 |
| 2025-03-24 | -3.96 |
| 2025-03-21 | -3.61 |
| 2025-03-20 | -3.53 |
| 2025-03-19 | -3.47 |
| 2025-03-18 | -3.32 |
| 2025-03-17 | -3.53 |
| 2025-03-14 | -3.77 |
| 2025-03-13 | -3.77 |
| 2025-03-12 | -3.77 |
| 2025-03-11 | -3.92 |
| 2025-03-10 | -3.90 |
| 2025-03-07 | -3.83 |
| 2025-03-06 | -3.89 |
| 2025-03-05 | -3.76 |
| 2025-03-04 | -3.92 |
| 2025-03-03 | -3.65 |